Agios Pharmaceuticals, Inc. announced that effective August 8, 2022, Jackie Fouse, Ph.D., will transition to the role of chair of the board of directors and Brian Goff will assume the role of chief executive officer. Goff will also serve as a member of Agios' board of directors. Current chairman, David Schenkein, M.D., will remain on the board as a director.

Goff joins Agios with more than thirty years of experience in the biopharmaceutical industry. Most recently he was executive vice president, chief commercial and global operations officer at Alexion Pharmaceuticals, where he was responsible for leading the global commercial and operations teams prior to the company's acquisition by AstraZeneca in July 2021. Before joining Alexion, Goff was chief operating officer and a member of the board of directors of Neurovance.

Prior to joining Neurovance, Goff served as Baxalta's executive vice president and president of the hematology division. He previously served with Baxter Healthcare Corporation as global hemophilia franchise head. Earlier in his career, Goff held positions of increasing responsibility in sales and marketing with Novartis Pharmaceuticals and the pharmaceutical division of Johnson & Johnson.

Goff has an MBA from the Wharton School at the University of Pennsylvania and a Bachelor of Arts from Skidmore College.